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Available online 24 August 2016The research ﬁeld of extracellular vesicles (EVs) is increasing immensely and the potential uses of EVs seem end-
less. They are found in large numbers in various body ﬂuids, and blood samplesmaywell serve as liquid biopsies.
However, these smallmembrane-derived entities of cellular origin are not straightforward toworkwith in regard
to isolation and characterization.
A broad range of relevant preanalytical issues was tested, with a focus on the phenotypic impact of smaller EVs.
The inﬂuences of the i) blood collection tube used, ii) incubation time before the initial centrifugation, iii) trans-
portation/physical stress, iv) storage temperature and time (short term and long term), v) choice of centrifuga-
tion protocol, vi) freeze-thaw cycles, and vii) exosome isolation procedure (ExoQuick™) were examined. To
identify the impact of the preanalytical treatments, the relative amounts (detected signal intensities of CD9-,
CD63- and/or CD81-positive) and phenotypes of small EVs were analyzed using the multiplexed antibody-
based microarray technology, termed the EV Array. The analysis encompassed 15 surface- or surface-related
markers, including CD9, CD63, CD81, CD142, and Annexin V.
This study revealed that samples collected in different blood collection tubes suffered to varying degrees from the
preanalytical treatments testedhere. There is no unequivocal answer to thequestions asked. However, in general,
the period of time and prospective transportation before the initial centrifugation, choice of centrifugation pro-
tocol, and storage temperature were observed to have major impacts on the samples. On the contrary, long-
term storage and freeze-thawing seemed to not have a critical inﬂuence. Hence, there are pros and cons of any
choice regarding sample collection and preparation andmay very well be analysis dependent. However, to com-
pare samples and results, it is important to ensure that all samples are of the same type and have been handled
similarly.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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In recent years, the interest in extracellular vesicles (EVs) has in-
creased immensely (Lötvall et al., 2014) and several studies have
shown the potential of utilizing them in a clinical setting, as diagnostic,
prognostic and as therapeutic agents, as reviewed by Revenfeld et al.
(Revenfeld et al., 2014) and György et al. (György et al., 2015). Further-
more, it has proven relevant to investigate immune cell-derived EVs, as
they appear to be important in several immunological relations
(Robbins and Morelli, 2014; Pugholm et al., 2016). EVs are small mem-
brane-derived entities produced from a diverse range of cell types
throughout the human body and, therefore, they are accessible in vari-
ous body ﬂuids (Caby et al., 2005; Admyre et al., 2007; Ogawa et al.,
2008; Gonzales et al., 2009). These vesicles can be divided into several
subgroups according to speciﬁc characteristics such as cellular origin,munology, Aalborg University
. This is an open access article undersize, protein/RNA composition, and biogenesis. When sorting using
the latter characteristic, the major subgroups are exosomes (30–
100 nm in diameter),microvesicles (MVs, 100–1000 nm) and apoptotic
bodies (500–4000 nm) (Pugholm et al., 2015), although MVs are also
often denoted microparticles (MPs) (Colombo et al., 2014). Each of
these subgroups possess numerous biological functions, and it is of in-
terest to determine them thoroughly to fully understand and utilize
the vesicular biology (Mulcahy et al., 2014).
Amajor challengewhenworkingwith EVs is the pronounced impact
that the preanalytical treatment has on the analysis outcome. Many in-
vestigators have highlighted the importance of a consistent protocol for
sample collection and preparation of EVs (Lacroix et al., 2010; György
et al., 2011; Yuana et al., 2011; Lötvall et al., 2014); however, it is also
relevant to consider which protocols are the best suited for the research
question addressed (Witwer et al., 2013). The choice of anticoagulant in
the blood collection tube has a considerable inﬂuence on the MV/MP
count (Jayachandran et al., 2012; György et al., 2014), as has the incuba-
tion time between blood collection and centrifugation, with an up to
80% increase in the MP count after 4 h (Lacroix et al., 2012). One verythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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standardized protocol for the preparation of platelet-free plasma (PFP)
has been suggested and it has shown to be of great importance when
analyzing MVs/MPs (Lacroix et al., 2012). However, it is hard to obtain
strictly platelet-free plasma and consequently it is urged that the same
protocol is applied to all samples that are to be compared (Witwer et
al., 2013).
Factors such as freezing, storage temperature and time, freeze-thaw
cycles, and transportation have been examined as well (György et al.,
2014; Jayachandran et al., 2012; Dey-Hazra et al., 2010; Lacroix et al.,
2012). Nevertheless, these features are somewhat inﬂuenced by the
method of isolation and subsequent choice of analysis. However, all of
these factors have primarily been investigated regarding MVs/MPs,
whereas there is little knowledge of the impact of the smaller vesicle
types (exosomes and exosome-like vesicles), especially in regard to
protein load.
Analysis of biobank samples is typically an ongoing process years
after collection; hence, a challenge is that the material is often quite
old. Other issues are that the samplesmay have been exposed to several
freeze-thaw cycles, and/or that the blood has been collected in tubes
thatweremost optimal for theﬁrst analysis inmind. Therefore, it is crit-
ical to determine the preanalytical impact as thoroughly as possible and
optimally for all types of analyses and for all types of EVs.
To determine the phenotypes of small EVs (sEVs), we have
established a protein microarray-based analysis, which is termed the
EV Array. This analysis platform, described by Jørgensen et al.
(Jørgensen et al., 2013), is optimized to catch and detect the smaller
types of EVs, such as exosomes and exosome-like vesicles, with diame-
ters up to ~150 nm. The detection is performed by utilizing a cocktail of
antibodies against the tetraspanins CD9, CD63, and CD81, which are
found on exosomes (Vlassov et al., 2012). The detection antibodies are
easily exchangeable, as are the capture antibodies, which can be com-
bined as desired and target up to 60 different markers simultaneously
in the same well (Jørgensen et al., 2015). The analysis is performed in
a 96-well setup and consumes only 10 μL of plasma, which makes the
platformvery cost-efﬁcient,multiplexed and high-throughput. It has al-
ready demonstrated great diagnostic potential in non-small cell lung
cancer (NSCLC), where cancer patients were distinguished from non-Fig. 1. Schematic overviewof the preanalytical factors tested. Five healthy volunteerswere include
EDTA, heparin, and serum. Unless otherwise speciﬁed, blood collection tubes were centrifuged
ASAP, as soon as possible; h, hour; RT, room temperature; rpm, rounds per minute.cancer lung-diseased patients with up to 75.3% accuracy (Jakobsen et
al., 2015; Sandfeld-Paulsen et al., 2016).
As Choi et al. (Choi et al., 2013) previously noted, a number of limi-
tations and challenges prevent EVs from being used diagnostically at
present. The goal is a rapidly performed and low-cost analysis platform,
whichmeets the limited decision time of the clinician. However, aspects
such as preanalytical standardization and development of a reliable
technique must be addressed initially. Here, we aim to complement
the current knowledge of preanalytical factors with a focus on pheno-
typing sEVs using an antibody-based platform designed to include 15
relevant markers. Using four different types of blood collection tubes,
blood from ﬁve healthy volunteers was analyzed and a broad range of
preanalytical factors was tested, as illustrated in Fig. 1.2. Materials and methods
2.1. Blood sampling
All research involving samples from human subjects was approved
by the local ethics legislation. Each person signed a written consent
form allowing for the use of their blood for research purposes. Venous
blood sampleswere obtained fromﬁve healthy volunteers and collected
into four different types of Vacuette® blood collection tubes (Greiner
Bio-One GmbH, Germany): CPDA (citrate phosphate dextrose adenine),
EDTA (K3EDTA, ethylenediaminetetraacetic acid), heparin (Lithium
Heparin) and serum (Z Serum Clot activator) tubes. The same number
of tubes was collected for each Vacuette® type from the same donor
at once within the same laboratory where the samples were to be han-
dled afterwards. Subsequently, the preanalytical treatments and tests
were performed simultaneously on all four Vacuette® types as speciﬁed
in the following.
Unless otherwise speciﬁed, the blood samples were centrifuged
once (1800g for 6 min at room temperature, RT) 1 h after collection,
before aliquoting and storage at −40 °C. Furthermore, the samples
were analyzed within a few days of sample collection. The same ex-
perienced operator carried out the handling of all samples and
analyses.d in the study and sampleswere assembled using the Vacuette® blood collection tubes CPDA,
once at 1800g for 6 min 1 h after collection and sample aliquots were stored at−40 °C.
Table 1
List of antibodies used to produce the EV Array for phenotyping; the Phenotyping Array.
Along with the company and catalogue number, the clones are given (when available).
CD, Cluster of Differentiation; TNF RI, Tumor Necrosis Factor Receptor 1; TSG101, Tumor
Susceptibility Gene 101; ICAM-1, Intercellular Adhesion Molecule 1.
Company Anti-human antibody Catalogue no. Clone
R&D Systems (MN, USA) AnnexinV AF399 –
CD19 MAB4867 4G7-2E3
CD106 MAB809 HAE-2Z
CD142 MAB2339 323514
TNF RI 840237 –
LifeSpan BioSciences (WA, USA) CD9 LS-C35418 –
CD42a LS-C45240 –
CD81 LS-B7347 –
Biolegend (CA, USA) Alix 634501 3A9
CD63 312002 MEM-259
Thermo Scientiﬁc (MA, USA) CD62E MA1-22165 –
BD Biosciences (CA, USA) CD3 555337 Hit3a
Abcam (MA, USA) Flotillin-1 ab41927 –
TSG101 ab117627 –
eBiosciences (CA, USA) ICAM-1 BMS1011 R6.5
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After collection of the blood samples, one tube of each Vacuette®
type from all ﬁve donors was centrifuged as soon as possible (ASAP)
within a fewminutes. An equivalent range of Vacuette® tubeswas incu-
bated at RT for 8 h and 24 h.
2.3. Transportation
To simulate transportation, one tube of each Vacuette® type from all
ﬁve donors was placed on an orbital shaker adjusted to 450 rpm during
the 1 h incubation period before centrifugation.
2.4. Additional centrifugations
One tube of each Vacuette® type fromall ﬁve donorswas exposed to
a two-step centrifugation. The samples were centrifuged at 2000g for
30 min at 15 °C. Then, two-thirds of the plasma/serum was transferred
to new15mL tubes and the centrifugationwas repeated. Finally, the top
two-thirds of the supernatant was aliquoted and stored.
For all ﬁve donors, one EDTA sample aliquot stored at−40 °C was
thawed and two volumes of 50 μL were transferred to new tubes; one
aliquot was centrifuged once at 14,000g for 2 min, and one was centri-
fuged twice at 2500g for 15 min. In those aliquots, 40 μL of sample
was removed between the two centrifugations and transferred to a
new tube. The obtained aliquots were analyzed immediately after the
centrifugations were completed.
2.5. Inﬂuence of storage conditions and freeze-thaw cycles
For all donors and Vacuette® types, aliquots from blood samples
were stored at different temperatures; RT, 4 °C, −20 °C, −40 °C,
−80 °C, and −160 °C. To test the inﬂuence of storage temperature
and time, blood was collected from the same donors twice with a time
gap of approximately 3 months. All samples were analyzed at the
same time and were deﬁned as short term and long term sample stor-
age, respectively.
Three aliquots from each donor and Vacuette® type stored at−40 °C
were thawed and refrozen one, two, or three times, respectively, to test
the inﬂuence of up to four freeze-thaw cycles.
2.6. ExoQuick™ isolation of exosomes
Two 50 μL aliquots from each donor and Vacuette® type stored at
−40 °C were designated for ExoQuick™ isolation of exosomes. One al-
iquot was handled before storage while the other was handled after
thawing, immediately before analysis. The precipitations were per-
formed according to the manufacturer's instructions. In short, 12 μL
ExoQuick™ Precipitation Solution (System Biosciences, CA, USA) was
added to each aliquot and the samples were incubated for 30 min at
4 °C. After centrifugation at 1500g for 30 min, the supernatants were
discarded. Each pellet was suspended in 50 μL sterile water.
2.7. Production of protein microarrays
Printing of the proteinmicroarray slides to the EV Array analysis was
performed on a SpotBot® Extreme Protein Edition Microarray Printer
using a 946MP4 pin (ArrayIt Corporation, CA, USA). As a positive con-
trol, 100 μg/mL of biotinylated human IgG was printed and PBS with
5%glycerolwas applied as the negative control. Antibodieswere printed
in triplicate on epoxy-coated glass slides (75.6 × 25.0 mm; SCHOTT
Nexterion, Germany), which were left to dry at RT overnight prior to
further analysis. Two types of EV Arrays were produced; one for pheno-
typing and one for semi-quantiﬁcation.2.7.1. EV Array for phenotyping
The anti-human antibodies used are listed in Table 1. All antibodies
were diluted in PBS with 5% glycerol and printed at 200 μg/mL. This
EV Array setup was used to analyze all samples and is denoted Pheno-
typing Array in the following.
2.7.2. EV Array for semi-quantiﬁcation
Amixture/cocktail of anti-human antibodies against CD9, CD63, and
CD81 (likewise included in the Phenotyping Array), each in the concen-
tration 100 μg/mL, was prepared with PBS containing 5% glycerol and
printed with the positive and negative controls. This EV Array was
used to analyze all samples and is denoted Cocktail Array in the
following.
2.8. EV Array analysis
The EV Array analyses were performed as described by Jørgensen et
al. (Jørgensen et al., 2013). In short, the printed slides were initially
blocked (50 mM ethanolamine, 100 mM Tris, 0.1% SDS, pH 9.0) prior
to incubation with 10 μL plasma or serum sample diluted (1:10) in
wash-buffer (0.05% Tween®20 in PBS). The incubation was performed
in Multi-Well Hybridization Cassettes (ArrayIt Corporation, CA, USA)
at RT for 2 h using an orbital shaker (450 rpm) and subsequently over-
night at 4 °C (no shaking). Following a short wash, the slides were incu-
bated for 2 h with a cocktail of biotinylated detection antibodies (anti-
human CD9, CD63, and CD81, LifeSpan BioSciences, WA, USA) diluted
1:1500 in wash-buffer. After washing, a subsequent 30 min incubation
step with Cy5-labelled streptavidin (Life Technologies, CA, USA) diluted
1:1500 in wash-buffer was carried out for detection. Prior to scanning,
the slides were washed ﬁrst in wash-buffer and then in deionized
water, followed by drying using a Microarray High-Speed Centrifuge
(ArrayIt Corporation, CA, USA). Scanning at 635 nm and subsequent de-
tection were performed as previously described.
2.9. Data analysis
The statistical analyses and the generation of graphs were per-
formed using Excel 2013 (Microsoft, WA, USA) and GraphPad Prism
6.04 (GraphPad Software Inc., CA, USA). Mean signal intensities of the
triplicate antibody spots were used and corrected for nonspeciﬁc bind-
ing from the detection antibodies by subtracting the mean signal inten-
sities from a blank well containing no sample. For each capturing
antibody, the corrected intensities were expressed in relation to the
mean signal of negative spots (containing PBS). The antibody signals
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sons, which were performed using non-parametric paired t-tests. The
data obtained using the Cocktail Array are a total of the signal intensities
of all three markers (CD9, CD63 and CD81). Hence, the data are treated
as one marker, as described above.
3. Results and discussion
Using the multiplexed, highly sensitive and high-throughput anti-
body-based platform of the EV Array, we have investigated a broad
range of preanalytical factors that could be of importance when analyz-
ing sEVs. Previously, we have examined the technical variability of the
EV Array and determined the coefﬁcient of variation as 2.9%
(Jørgensen et al., 2015). In this study, we have only focused on sEVs pos-
itive for CD9, CD63, and/or CD81, as these molecules are used for detec-
tion with the EV Array in the current setup. Since the three markers are
detected with a cocktail of antibodies against them, the resulting data
are a summation of the obtained signal intensities. The study is based
on plasma fromﬁve healthydonors. As previously described, the plasma
content of sEVs vary greatly among individuals (Jørgensen et al., 2013;
Bæk et al., 2016); consequently, the results presented here do not ac-
count for this variation. Hence, the data are presented by dot plots to
best illustrate the overall inﬂuence of the preanalytical treatments on
the content of sEVs.
Generally, using only one technique is discouraged, whereas addi-
tional analyses could have contributed to a stronger data-set. However,
often-used quantitative analyses such as Nano Tracking Analysis and
Scanning Ion Occlusion Sensing are observed to be inﬂuenced by lipo-
somes/lipoproteins and other aggregates in plasma samples, whichFig. 2.The inﬂuence of incubation time before initial centrifugation. Blood sampleswere incubat
as soon as possible (ASAP) after sampling. The data are presented as log2 transformed relative
using the Cocktail Array for the Vacuette® blood collection tubes CPDA, EDTA, heparin, and s
collected in CPDA and EDTA blood collection tubes are illustrated using box plots indicating
Array. Statistically signiﬁcant differences are indicated with p-values: *p b 0.05; **p b 0.01.complicates the interpretation of the results. When presenting data ob-
tained with the Cocktail Array, the outcome is semi-quantitative and is
therefore an indicator for the quantity of the detected sEVs. Hence, the
Cocktail Array was implemented as an attempt to compensate for the
missing additional analysis.
3.1. Does the time between blood sampling and centrifugation have an in-
ﬂuence on the sEVs?
To test whether the time range from blood collection to isolation of
plasma/serum has an impact on the subsequent analysis, samples
from all donors and blood collection tubes were incubated at RT for
1 h, 8 h, and 24 h prior to centrifugation. These samples were compared
with samples centrifuged immediately after sample collection, as illus-
trated in Fig. 2, although it was not possible to obtain useful samples
from the serum tubes at this time point.
The mean values for the detected signal intensities of sEVs in sam-
ples collected in heparin and serum tubes displayed no signiﬁcant
changes over time (Fig. 2A). However, for samples collected in CPDA
and EDTA tubes, the incubation time had an obvious inﬂuence on the
content of sEVs. The trends were similar for the two glass types; when
compared to the samples centrifuged ASAP, the detected signal intensi-
ties of sEVs underwent a great decrease after a 1 h incubation. After an
8 h incubation, the detected signal intensities of the sEVs had increased,
and after 24 h, the intensities were similar to the values obtained when
the centrifugation was performed ASAP. The apparent decrease in the
signal intensities of the sEVs happening within the ﬁrst hour of incuba-
tion could be speculated to be caused by the activation of the platelets
present in the samples. EDTA almost immediately activates platelets,ed at RT for 1 h, 8 h, and 24h before centrifugation and comparedwith samples centrifuged
intensities of all ﬁve donors. A) Dot plots illustrating the semi-quantitative data obtained
erum. The lines connect the samples from each individual donor. B) Data from samples
mean, min and max values. Data are shown for all markers included in the Phenotyping
Fig. 3. The inﬂuence of transporting the blood samples. Blood samples were placed on an
orbital shaker for 1 h at 450 rpm to simulate transport and were compared with samples
incubated 1 h without shaking. The data are presented as log2 transformed relative
intensities of all ﬁve donors illustrated by dot plots where the lines connect the samples
from each individual donor. A) Semi-quantitative data obtained using the Cocktail Array
for the Vacuette® blood collection tubes CPDA, EDTA, heparin, and serum. B) Data from
samples collected in EDTA blood collection tubes. Data are shown for the four markers
Annexin V, CD19, TNF RI, and CD106 obtained with the Phenotyping Array. Statistically
signiﬁcant differences are indicated with p-values: *p b 0.05; **p b 0.01; ***p b 0.001.
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causes a less spontaneous activation; hence, when blood is collected
into citrate, there is initially little or no change in platelet shape and vol-
ume. However, subsequently the platelets slowly adopt a spherical
shape and, as in EDTA tubes, swell progressively over a period of 1–
2 h (Ahnadi et al., 2003). Using scattering measurements, Macey et al.
found that the mean platelet volume decreased signiﬁcantly during
the ﬁrst 30–60 min when CPDA and EDTA tubes were used. The initial
mean platelet volume was regained after 3 h. During the process of ac-
tivation and change of shape, the platelets rearrange their membrane
structures and enhance the amounts of several of their surface mole-
cules (Golanski et al., 1996). Taken together, it could be speculated
that the sEVs present in the CPDA and EDTA blood collection tubes are
adhering to the platelets during the process of activation and, therefore,
are removed with the cells during centrifugation.When the platelet ac-
tivation and surface rearrangements have been undergone, the nonspe-
ciﬁc sEV adhesion is probably relieved by the aggregation of platelets
and leukocytes, which could explain the observed increase in detected
signal intensities of sEVs after 8 h and 24 h.
During the process of activation, platelets degranulate and produce
large amounts of Annexin V positive MPs (size range N 300 nm)
(Golanski et al., 1996; Yuana et al., 2011). Lacroix et al. found that the
MP count in citrated plasma increased within the ﬁrst hour compared
to the samples centrifuged within minutes. After a 4 h incubation, the
MP count had increased approximately 80% (Lacroix et al., 2012). In
this study, we measured the sEVs presenting CD9, CD63 and/or CD81
on the surface, whereas Lacroix et al. focused on the larger MPs deﬁned
as Annexin V positive vesicles, which explains the disagreements in the
results.
In Fig. 2B, the signal intensities obtained with the more speciﬁc Phe-
notyping Array of the individual EV markers from CPDA and EDTA sam-
ples incubated for 1 h and 24 h are shown. In general, for both sample
types, the tendency leans towards an increase in speciﬁc sEV signal in-
tensitieswhen increasing the incubation time from1 h to 24 h, although
only CD9 changes signiﬁcantly (p b 0.05). However, CD19, CD42a and
ICAM-1 are exceptions to this trend, of which the platelet glycoprotein
CD42a diverged the most.
When collecting samples in the clinic, it is difﬁcult to perform the
centrifugation within minutes. Of the tested time delays in this study,
the 1 h incubation resulted in the lowest detected signal intensities of
sEVs, probably because the sEVs are removed with the cells. The stan-
dard incubation time in this studywas set to 1 h,whichmatches the rec-
ommendations from both the manufacturer of the blood collection
tubes and the study of Lacroix et al. (Lacroix et al., 2012). Because of
the seemingly induced events in the CPDA and EDTA blood collection
tubes, we suggest to either perform the centrifugation immediately
after the collection or wait 24 h before centrifugation to avoid the
suspected removal of sEVs.3.2. Does transportation alter the sEV content in blood samples?
To examine the impact of transportation or similar mechanical
stress, the blood samples were exposed to agitation for 1 h using an or-
bital shaker (450 rpm), which should simulate vehicle transportation
from one facility to another. The results are shown in Fig. 3.
A general tendency towards a change in the content of sEVs was
seen when the blood samples were transported/stressed before isola-
tion of the plasma/serum. The use of CPDA blood collection tubes led
to an increase in the detected signal intensities of the sEVs that was
not statistically signiﬁcant (Fig. 3A). Two other studies conﬁrm this ten-
dency observed in the citrate-containing samples, even though other
types of citrate-containing tubes were used and the transport simula-
tions were performed differently (Lacroix et al., 2012; György et al.,
2014). Both of these studies targeted Annexin V positiveMPs and the in-
creases observed were of major orders compared to the increasespresented for the CPDA samples here, which, however, are representa-
tive for sEVs. Hence, some differences are to be expected.
Likewise, when collecting blood in EDTA tubes, increased signal in-
tensities were observed in the transported/stressed samples in the
data obtained with the Cocktail Array (Fig. 3A); however, here the in-
creasewas signiﬁcant (p b 0.001). The data obtainedwith the Phenotyp-
ing Array revealed that the markers providing the main contribution to
the overall increasing signal were Annexin V, CD19, TNF RI, and CD106
(Fig. 3B). Annexin V is often used to identify MVs/MPs; however, it
has also been observed in the small EV subsets (Kowal et al., 2016).
The fact that AnnexinV in this study contributed to themassive increase
could indicate that smaller MVs were captured on the EV Array along
with exosomes and exosome-like vesicles. The signiﬁcant increase of
the other three markers indicates that other cells than platelets are
stressed during transport as well, although platelets are often consid-
ered as the main contributor of in vitro vesiculation (Bode et al.,
1991). The remaining markers detected with the Phenotyping Array
also increased; however, these differences were not statistically signiﬁ-
cant (data not shown). The observed increases could be related to the
platelet activation events described in Section 3.1. The lowest detected
signal intensities for the CPDA and EDTA plasma samples were seen
when samples were centrifuged after 1 h of collection. We speculate
that the sEVs adhere to the platelets during the string of activation
events and are subsequently released within the following hours. The
physical impact of the transport simulation could be causing the sEVs
to loosen more rapidly, which would explain the observed increase.
Since transportation does inﬂuence EV analyses, the preferable op-
tionwould be to centrifuge the samples at the site of collection. Howev-
er, a centrifuge is not always at hand and transportation may be
impossible to avoid. Lacroix et al. (Lacroix et al., 2012) did, however,
succeed in making the inﬂuence insigniﬁcant by immobilizing the
blood collection tubes in a vertical fashion. This was shown for citrated
plasma and whether it is likewise effective for other types of blood col-
lection tubes is uncertain. Nevertheless, it could be an acceptable and
easily adaptable solution and should be tested further.3.3. What impact does storage temperature and period have on sEVs?
To include samples from a pre-collected biobank in a study, a rele-
vant question to answer is what inﬂuence different storage tempera-
tures and periods have on the samples in relation to the type of blood
collection tube used. Six storage temperatures ranging from−160 °C
to RT were tested at two time points representing short term (days)
and long term (months) storage. The results obtained using the Cocktail
Array are presented in Fig. 4.
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come of the analysis. The detected signal intensities of sEVs change al-
most randomly when the temperature and type of blood collection
tube change, although some trends can be identiﬁed (Fig. 4A and B). Ini-
tially, the differences in the detected signal intensities are less pro-
nounced when disregarding the results from samples stored at RT and
4 °C. In doing so, the progress of the graphs is somewhat similar within
the same Vacuette® types comparing short term with long term stor-
age. However, the results obtained from serum samples diverge, in
that the signal intensities of sEVs decrease with lower storage tempera-
ture under short term storage (Fig. 4A), whereas the levels appearmore
constant under long term storage (Fig. 4B). When freezing the samples,
it seems that the most stable samples are the ones collected in heparin
blood collection tubes and the most unstable are the ones collected in
EDTA tubes.
The samples stored at RT and 4 °C displayed a trend towards increas-
ing signal intensities with lower temperatures for long term storage
(Fig. 4B) but decreasing signal intensities for short term storage (Fig.
4A). In the latter situation, CPDA plasma samples present somewhat
constant signal intensities.
When analyzing the data obtainedwith the EV Array, signals obtain-
ed from corresponding antibody spots in a well only containing wash
buffer were utilized to account for nonspeciﬁc binding of the detection
antibodies. After subtracting the mean signal obtained from the blank
well from the corresponding antibody-spot in the sample well, the
corrected signal was divided by the mean signal from the blank spots
in the same samplewell. This accounts for the different background sig-
nals individuals may induce; hence, limiting the background noise can
be of considerable importance.
In Fig. 4C, the raw scanning of the microarray spots are visualized
from the samples stored short term. As the individual sampleFig. 4. The impact of storage temperature and period. Blood samples obtained at two different
−160 °C) after isolation of plasma/serum for either A) short term (days) or B) long term (m
collection tubes CPDA, EDTA, heparin, and serum. Data are presented as log2 transformed r
samples from each individual donor. Statistically signiﬁcant differences are indicated with
Unreﬁned microarray spots from one representative donor obtained from Cocktail Array slide
storage.background noise is accounted for when calculating the relative
intensities, the results are highly inﬂuenced by intense backgrounds.
As observed in Fig. 4C, the background intensities in the EDTA
plasma samples vary greatly with the most severe examples seen
for the lowest temperatures. This explains why EDTA plasma
samples are more inﬂuenced by different temperatures, as observed
in Fig. 4A.
The literature is not in agreement as to the effect of temperature and
storage period on EVs. One study concluded that freezing of plasma at
either−40 °C or−80 °C had no relevant impact onMV countwhen iso-
lated from PPP (platelet-poor plasma) or PFP (Jayachandran et al.,
2012). These samples were stored for more than one year. If the MVs
were isolated, however, they could be stored at RT for a few days with-
out being unstable, whereas freezing led to lower counts. In the study of
Dey-Hazra et al. (Dey-Hazra et al., 2010), the MP count obtained from
citrated plasma stored at−80 °C changed over time, increasing within
the ﬁrst twoweeks and then decreasing. Hence, they propose that fresh
samples are the most ideal. Lacroix et al. (Lacroix et al., 2012) similarly
observed an increase in MP count in citrated plasma samples after one
week of storage at the same temperature (−80 °C) followed by a de-
crease, though the changes were less pronounced. However, after one
year of storage, the change in MP count was only minor. Hence, the
study of Lacroix et al. agrees with the study of Jayachandran et al.
(Jayachandran et al., 2012) that long term storage has only a minor in-
ﬂuence on the EV count.
Although we observed contrary results for short and long term stor-
age, and none of the mentioned studies (ours as well as others) fully
agree on what should be practice, it should be kept in mind that the
compared results were obtained for different EV populations. However,
some agreement can be found. It is rarely possible to use fresh samples
in large-scale studies. Neither is it always possible to inﬂuence thetime points were stored at different temperatures (RT, 4 °C,−20 °C,−40 °C,−80 °C, and
onths) periods. The data were obtained using the Cocktail Array for the Vacuette® blood
elative intensities of all ﬁve donors illustrated by dot plots where the lines connect the
p-values, which are * unless otherwise detailed: *p b 0.05; **p b 0.01; ***p b 0.001. C)
s for all Vacuette® blood collection tubes and all storage temperatures after short term
Fig. 5. The outcome of one- versus two-step centrifugations. Blood samples collected in
the Vacuette® tubes CPDA, EDTA, heparin, and serum were exposed to two different
centrifugation protocols; one-step (1800g for 6 min, standard protocol) or two-step
(2 × 2000g for 30 min) before storage (A, B, and C). The data shown are obtained using
the Cocktail Array. A) Semi-quantitative data are presented as log2 transformed relative
intensities of all ﬁve donors illustrated by dot plots where the lines connect the samples
from each individual donor. B) The corresponding background intensities obtained from
the same analysis shown by similar dot plots. Statistically signiﬁcant differences are
indicated with p-values: *p b 0.05; **p b 0.01; ***p b 0.001. C) Unreﬁned microarray
spots from one representative donor for all Vacuette® blood collection tubes illustrating
the visual inﬂuence of spot versus background intensity. D) EDTA sample aliquots stored
after one-step centrifugation were exposed to additional centrifugations immediately
before analysis. Samples centrifuged using a new one-step (14,000g for 2 min) or new
two-step (2 × 2500g for 15 min) centrifugation procedure were compared to non-
centrifuged samples. Shown are unreﬁned microarray spots from one representative
donor.
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Nevertheless, samples should only be compared if they are of the
same type and have been stored similarly.
3.4. Is the analysis of sEVs inﬂuenced by the centrifugation protocol of
choice?
As mentioned, centrifugation procedures for MPs/MVs are well de-
scribed, and a protocol for the achievement of PFP has been suggested
(2× 2500g for 15min) (Lacroix et al., 2012). The elimination of platelets
before storage is of great importancewhenworking with the larger EVs
such as MPs/MVs, as residual platelets are able to vesiculate in vitro
(Bode et al., 1991), which can alter the subsequent analysis results in-
conveniently (Artoni et al., 2012; Piccin et al., 2007). However, many
different protocols are used to obtain PFP. Trummer et al. (Trummer
et al., 2009) used a combined low (1500g for 15 min) and high
(14,000g for 2 min) speed approach, whereas Nielsen et al. (Nielsen et
al., 2014) combined three low speed centrifugations (1800g for
10 min; 3000g for 15 min; 3000g for 5 min) to eliminate residual
platelets.
To determine if restricting the content of platelets could serve as an
advantage to sEV analyses (such as the EV Array), an alternative centri-
fugation protocol (2 × 2000g for 30min)was implemented. This centri-
fugation approach was adapted from Pereira et al. (Pereira et al., 2006),
who aimed for PFP. This alternative protocol was compared to our stan-
dard centrifugation protocol (1800g for 6 min). The results are present-
ed in Fig. 5A-C.
In Fig. 5A, a signiﬁcant difference in the detected signal intensities of
sEVs are seen for samples collected in CPDA and EDTA blood collection
tubes when changing our standard one-step centrifugation protocol to
the alternative two-step protocol. In Fig. 5B, the corresponding back-
ground signal intensities are illustrated, which explains the pronounced
variation in the CPDA and EDTA plasma samples. Whereas the back-
ground intensities for the plasma samples centrifuged by the two-step
protocol were insigniﬁcant, the plasma samples centrifuged by our
standard one-step protocol displayed very high background intensities,
in particular for the EDTA plasma samples. The observation that espe-
cially EDTA plasma samples can beneﬁt from the two-step centrifuga-
tion protocol is conﬁrmed in Fig. 5C, which displays the unreﬁned
microarray spots from the analysis. The background intensity was in-
deed positively inﬂuenced by the alternative protocol.
Having realized the beneﬁt of incorporating the two-step centrifuga-
tion protocol when collecting EDTA plasma samples, it was relevant to
determine whether it was possible to limit the background noise in al-
ready frozen samples. Hence, EDTA plasma sample aliquots were ex-
posed to either a short, high-speed one-step centrifugation (14,000g
for 2 min) or a longer, low-speed two-step centrifugation procedure
(2 × 2500g for 15 min) immediately before analysis and compared to
sample aliquots not exposed to post-storage centrifugation (Fig. 5D).
Again, EDTA plasma samples beneﬁtted from expanded centrifugation
procedures. However, based on the appearance of the unreﬁned micro-
array spots, the two centrifugation procedures were equally valuable.
Even though the analysis outcome did beneﬁt strikingly at some
points from the alternative two-step centrifugation procedure, the re-
sults obtained with the Phenotyping Array revealed that the residual
platelets performing in vitro vesiculation do not alter the analysis out-
come of the EV Array analysis of sEVs once the initial centrifugation is
performed (data not shown). If this had been the case, all four sample
types would have beneﬁtted from the alternative protocol. Further-
more, it was possible to regain clear antibody signals from EDTA plasma
samples by eliminating most of the background noise. The ensuing sig-
nals were comparable to the ones obtained from the pre-storage double
centrifugation (data not shown).
As mentioned, there is a demand for analyses with short perfor-
mance times. Hence, adapting unnecessary preanalytical steps is not de-
sirable. Since only two of the tested blood collection tubes beneﬁttedfrom the expanded centrifugation procedure it could be relevant to de-
sign individual preanalytical protocols for each type of blood collection
tube.
3.5. Do several freeze-thaw cycles affect the contents of sEVs?
In continuation of the questions addressed in Section 3.3 relating to
storage temperature and period, it is of interest to determine whether
samples can be re-frozen and thereby reused. To examine this issue,
sample aliquots from all donors and blood collection tubes were ex-
posed to freezing and thawing either one, two, three or four times.
The outcome of the subsequent Cocktail Array analysis is illustrated in
Fig. 6.
Some minor changes in the contents of the sEVs were observed
among aliquots of the same sample type, of which fewwere statistically
signiﬁcant (p b 0.05). The changes were mostly minor increases;
Fig. 6. The inﬂuence of freezing and thawing. Sample aliquots from blood collected in the
Vacuette® tubes CPDA, EDTA, heparin, and serum for all ﬁve donors were thawed and
refrozen either 2, 3 or 4 times. The samples are compared to samples thawed only once.
Shown are data obtained using the Cocktail Array presented as log2 transformed relative
intensities of all ﬁve donors illustrated by dot plots. The lines connect the samples from
each individual donor. Statistically signiﬁcant differences are indicated with p-values:
*p b 0.05.
Fig. 7. Exosome isolation using ExoQuick™ Precipitation Solution. Exosome isolation was
performed on sample aliquots from blood collected in the Vacuette® tubes CPDA, EDTA,
heparin, and serum from all ﬁve donors using ExoQuick™ Precipitation Solution. The
isolation was performed either before storage or immediately before analysis (after
storage). The results are compared to results achieved from crude plasma/serum
samples. Data are presented as log2 transformed relative intensities of all ﬁve donors
illustrated by dot plots where the lines connect the samples from each individual donor.
A) Data obtained using the Cocktail Array. Inserted are the unreﬁned microarray spots
from one representative donor. B) Data for the markers Annexin V, CD9, TNF RI, CD142,
CD42a, and ICAM-1 obtained with the Phenotyping Array from samples collected in
heparin blood collection tubes. Statistically signiﬁcant differences are indicated with p-
values: *p b 0.05; **p b 0.01; ***p b 0.001.
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and serum samples (data not shown), which would contribute to the
observed increase. Freeze-thaw cycles therefore had only a small inﬂu-
ence on the sEV contents. Hence, it is possible to reuse samples of the
four tested blood sample types without compromising the analysis out-
come in a critical manner, at least up to four times. This is conﬁrmed by
Jayachandran et al. (Jayachandran et al., 2012)who concluded that plas-
ma samples could be freeze-thawed up to three times without altering
the MV counts.
3.6. Does the ExoQuick™ isolation procedure inﬂuence the EV Array
outcome?
Of the increasing interest in the ﬁeld of EVs, themost attention is fo-
cused on exosomes. However, exosomes are hard to purify, as isolates
are generally contaminated with other EV subsets (Lötvall et al.,
2014). Along with the increasing interest in exosome research, an
equally growing demand for isolation techniques has arisen. Various
kits and solutions to easily obtain exosome precipitates are now com-
mercially available. One widely tested product is ExoQuick™ Precipita-
tion Solution. Here, we aimed to determine if the EV Array and similar
antibody-based analyses can beneﬁt from such a product and hence
narrow the research to exosomes exclusively. The results are presented
in Fig. 7.
The ExoQuick™ isolation of exosomes was performed either before
or after freezing of the sample aliquots, and the results were compared
to analyses of crude non-isolated plasma/serum samples (Fig. 7A). For
CPDA plasma samples, a minor non-signiﬁcant increase was observed
when performing the isolation before storage compared to non-isolated
samples. The detected signal intensities of sEVswere, however, lower in
samples exposed to isolation after freezing, although not signiﬁcantly.
In the case of EDTA plasma samples, highly signiﬁcant (p b 0.01) in-
creases were obtained using ExoQuick™ isolation, regardless of wheth-
er it was carried out before or after storage. However, the unreﬁned
microarray spots revealed that the increase ismainly caused by a reduc-
tion in the background noise. The opposite is the case for CPDA plasma
samples, where the background suffered a minor impairment in the
precipitates. When performing exosome isolation and therebyeliminating other CD9-, CD63-, and/or CD81-containing vesicles, a de-
crease in the detected EV signal intensities would be expected. This
was not the case for CPDA and EDTA plasma samples, unlike the heparin
plasma samples. The decreases in the signal intensities in the precipitat-
ed heparin plasma samples were statistically signiﬁcant, either p b 0.01
or p b 0.05 for the isolations performed before or after freezing, respec-
tively. In Fig. 7B, the data obtained with the Phenotyping Array of the EV
markers contributing signiﬁcantly to the decrease in heparin plasma
precipitates are displayed. Here, the MV/MP marker Annexin V is pres-
ent along with the platelet-associated CD42a and CD142, which meets
the expectations of the exosome isolation procedure. However, for the
two platelet-associated markers, the decrease in signal intensity was
primarily observed when the isolation was performed before storage.
Furthermore, the immune-related markers TNF RI and ICAM-1 and in
particular the exosome-associated marker CD9 contribute to the de-
crease as well. Although CD9 was once regarded a speciﬁc exosome
marker it has been identiﬁed in other EV subsets (Bobrie et al., 2012;
Kowal et al., 2016). Hence, this could indicate that CD9-bearing non-
exosome sEVs are removed when using the ExoQuick™ Precipitation
Solution on heparin plasma samples. In the case of performing the isola-
tion on serum samples, the overall impression is that the sEV content is
less inﬂuenced by the isolation procedure in this sample type. Only one
sample was clearly affected by the procedure, resulting in a major de-
crease in the detected signal intensities.
In a study of exosome isolation methods, Lobb et al. (Lobb et al.,
2015) concluded that the ExoQuick™ precipitation was inadequate
compared to othermethods and they observed a highdegree of albumin
contamination. They proposed ultraﬁltration combinedwith size exclu-
sion chromatography as a better method of isolation. Likewise, Van
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Gradient is a better choice because it leads to a higher purity of
exosome-speciﬁc protein as well as RNA yield compared to the
ExoQuick™ Precipitation Solution, among others. Our results agree
that the ExoQuick™ product might not be the best suited method for
exosome isolation, since only heparin plasma samples beneﬁtted con-
vincingly from the isolation procedure.
3.7. Which blood collection tube is the best suitable for sEV analyses?
From the results presented here, heparin plasma showed good qual-
ities in all the tests. Neither of the other tested blood collection tubes
displayed the same degree of stability. However, as reviewed byWitwer
et al. (Witwer et al., 2013), the use of heparin-based anticoagulants is
discouraged for a number of reasons. Platelet activation is one reason
(Gao et al., 2011), which is highly undesirable in EV analyses in general.
Another inconvenient property of heparin is that it can block EV uptake
by other cells (Maguire et al., 2012), which is a problemwhen studying
the biological functionalities of EVs. The latter issue may not be a prob-
lem in the analytical phenotyping aspect described here.
Other studies have tested the use of several types of blood collection
tubes as well, but mainly focus on MVs/MPs analyzed by ﬂow cytome-
try. György et al. (György et al., 2014) tested different types of citrate-
containing tubes and concluded that ACD-A plasma seemed the most
suitable for MP analyses, which is partly supported by Lacroix et al.
(Lacroix et al., 2012), who also recommended citrated plasma. The
study of Jayachandran et al. (Jayachandran et al., 2012), on the other
hand, showed that EDTA resulted in lower MV (including platelet-de-
rived) counts comparedwith the other tested anticoagulants and prote-
ase inhibitors. In our hands and with the presented analysis approach
targeting the smaller EV populations, the EDTA plasma samples were
the most troublesome to work with. However, the addition of a few
extra steps to the sample preparation made it possible to overcome
most issues and to obtain useful results.
The number of EV research projects performed on plasma samples
outnumber those involving EV analyses of serum samples. Our results
do not exclude serum samples as useless, which, in fact, seemed less in-
ﬂuenced bymost of the tested factors compared to the often used EDTA
and CPDA samples. Actually, on the basis of the results obtained by the
EV Array technology presented here, none of the tested blood collection
tubes can be ruled out as useless. There are pros and cons of using any of
these blood collection tubes, which affect the data outcome differently.
Hence, it is very critical to keep the sample type constant when
collecting for a study.
4. Concluding remarks
In this study, we have tried to clarify as many aspects of the
preanalytical impact of sEVs as possible. Nevertheless, it is important
to keep in mind that the statements given here are applicable only for
the EV Array analysis andmay not be directly transferable to other phe-
notyping analyses. However, it may be reasonable to assume it applies
to other antibody-based methods such as ELISA.
No unequivocal answer exists as to which type of blood collection
tube should be used, how it should be stored and for how long it is ac-
ceptable to use the samples etc. Any change in the sample collection
process may have an impact on the analysis outcome. At ﬁrst, it is im-
portant to stick to the chosen type of blood collection tube, as a change
will result in an altered data outcome that cannot be used for compari-
son. Next, it is critical to keep the period before the initial centrifugation
constant, as the content of sEVs seems to be affected by the chemistry
that occurs when the blood meets the anticoagulants. This is especially
evident in the case of CPDA and EDTA plasma samples, which should be
handled either ASAP or the next day (24 h later). This observation, how-
ever, contradicts the recommended 1–2 h time frame from the manu-
facturer of the blood collection tubes and from the study of Lacroix(Lacroix et al., 2012) involving larger EV populations. If the samples
need to be transported before the initial centrifugation, it is important
that it applies for all samples. Because of the effect it has on the samples
(most pronounced for CPDA and EDTA plasma samples), the most opti-
mal situationwould be to centrifuge and store the samples at the site of
collection and subsequently transfer all samples together in a frozen
state. In this regard, even the storage temperature inﬂuences the signal
intensities of the sEVs in the samples, which is evident for all the sample
types tested. Hence, frozen samples should not be compared with fresh
samples and the chosen storage temperature should likewise be kept
constant. We observed no major problems with long term storage of
frozen samples for anyof the tested blood collection tubes. The same ap-
plies for the reuse of frozen samples up to 4 times, although freeze-thaw
cycles should be kept at a minimum. Furthermore, the choice of centri-
fugation protocol has an impact on the analysis of sEVs. Both CPDA and
EDTA plasma samples beneﬁt from applying a two-step centrifugation
procedure (2 × 2000g for 30 min), whereas for heparin plasma and
serum samples a one-step centrifugation protocol (1800g for 6 min) is
sufﬁcient.
Because the tested preanalytical treatments had different degrees of
impact on the analysis outcome, it could be relevant to adjust the sam-
ple preparation protocol in relation to the blood collection tube used.Conﬂict of interest
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